HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Islet Cell Adenoma (Islet Cell Tumors)

A benign tumor of the pancreatic ISLET CELLS. Usually it involves the INSULIN-producing PANCREATIC BETA CELLS, as in INSULINOMA, resulting in HYPERINSULINISM.
Also Known As:
Islet Cell Tumors; Adenoma, Islet Cell; Island Cell Tumor; Adenomas, Islet Cell; Island Cell Tumors; Islet Cell Adenomas; Langerhans Tumor Islet; Nesidioblastomas; Tumor Islet, Langerhans; Tumor, Island Cell; Tumor, Islet Cell; Tumors, Island Cell; Tumors, Islet Cell; Islet Cell Tumor; Islet of Langerhans Tumor; Nesidioblastoma; Pancreatic Islet Cell Tumors
Networked: 628 relevant articles (15 outcomes, 54 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neoplasms (Cancer)
2. Hypoglycemia (Reactive Hypoglycemia)
3. Carcinoid Tumor (Carcinoid)
4. Neoplasms, Cystic, Mucinous, and Serous
5. Neoplasm Metastasis (Metastasis)

Experts

1. Fukuda, Izumi: 13 articles (03/2022 - 08/2006)
2. Hizuka, Naomi: 5 articles (01/2021 - 08/2006)
3. Bartsch, Detlef K: 5 articles (01/2014 - 03/2011)
4. Fendrich, Volker: 5 articles (01/2014 - 03/2011)
5. Waldmann, Jens: 5 articles (01/2014 - 03/2011)
6. Rehm, Johannes: 4 articles (03/2012 - 03/2011)
7. Lauth, Matthias: 3 articles (01/2014 - 03/2011)
8. Buchholz, Malte: 3 articles (03/2012 - 03/2011)
9. Imamura, Masayuki: 3 articles (12/2005 - 01/2002)
10. Antoku, Shinichi: 2 articles (05/2021 - 01/2021)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Islet Cell Adenoma:
1. Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
2. Streptozocin (Streptozotocin)FDA Link
3. Insulin-Like Growth Factor II (Somatomedin A)IBA
4. Hormones (Hormone)IBA
5. GastrinsIBA
6. Fluorouracil (Carac)FDA LinkGeneric
08/01/1994 - "5-Fluorouracil (5-FU) has shown modest single-agent activity in patients with carcinoid or islet cell tumors. "
08/01/1994 - "A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors."
11/01/1998 - "In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant 5-fluorouracil (5-FU)-based chemoradiation in 39 "resectable" patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; gemcitabine has shown promise in alleviating tumor-related symptoms with a significantly better "clinical benefit response" than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of p53 and TGF-beta; a p21-adenovirus (rAD-p21) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-p21."
7. Adrenocorticotropic Hormone (ACTH)FDA Link
8. Octreotide (Sandostatin)FDA LinkGeneric
9. AntigensIBA
10. Transforming Growth Factor beta (TGF-beta)IBA
11/01/1998 - "In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant 5-fluorouracil (5-FU)-based chemoradiation in 39 "resectable" patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; gemcitabine has shown promise in alleviating tumor-related symptoms with a significantly better "clinical benefit response" than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of p53 and TGF-beta; a p21-adenovirus (rAD-p21) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-p21."

Therapies and Procedures

1. Therapeutics
2. Pancreatectomy
3. Radiotherapy
4. Laparotomy
5. Pancreaticoduodenectomy